LNTH:NSD-Lantheus Holdings Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 107.98

Change

-0.76 (-0.70)%

Market Cap

USD 7.11B

Volume

0.55M

Analyst Target

USD 21.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-05 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
UTHR United Therapeutics Corporatio..

+4.10 (+1.39%)

USD 13.14B
NBIX Neurocrine Biosciences Inc

+0.07 (+0.06%)

USD 9.54B
VTRS Viatris Inc

-0.06 (-0.69%)

USD 9.00B
ALKS Alkermes Plc

-0.38 (-1.20%)

USD 4.74B
HCM HUTCHMED DRC

+0.12 (+0.80%)

USD 2.63B
ALVO Alvotech

+0.11 (+1.34%)

USD 2.57B
SUPN Supernus Pharmaceuticals Inc

-0.45 (-1.37%)

USD 1.80B
ANIP ANI Pharmaceuticals Inc

-0.39 (-0.53%)

USD 1.51B
INDV Indivior PLC Ordinary Shares

-0.08 (-0.67%)

USD 1.44B
BCRX BioCryst Pharmaceuticals Inc

+2.10 (+23.52%)

USD 1.43B

ETFs Containing LNTH

WELL:PA HAN-GINS Indxx Healthcare.. 3.78 % 0.00 %

-0.01 (-0.08%)

N/A
WELL:SW HAN-GINS Indxx Healthcare.. 3.78 % 0.00 %

-0.07 (-0.08%)

N/A
MEDI Harbor Health Care ETF 3.12 % 0.00 %

-0.09 (-0.08%)

USD 0.01B
GRPM Invesco S&P MidCap 400 GA.. 3.01 % 0.00 %

-0.08 (-0.08%)

N/A
JSMD Janus Henderson Small/Mid.. 1.71 % 0.50 %

-0.30 (-0.08%)

USD 0.44B
WELP:LSE HAN-GINS Indxx Healthcare.. 1.39 % 0.00 %

N/A

N/A
QWST 1.37 % 0.00 %

N/A

N/A
FNY First Trust Mid Cap Growt.. 0.00 % 0.70 %

-0.22 (-0.08%)

USD 0.35B
IWO iShares Russell 2000 Grow.. 0.00 % 0.24 %

-1.58 (-0.08%)

N/A
RFG Invesco S&P MidCap 400® .. 0.00 % 0.35 %

+0.01 (+-0.08%)

N/A
RNSC First Trust Small Cap US .. 0.00 % 0.60 %

N/A

USD 0.03B
AGED:LSE iShares Ageing Population.. 0.00 % 0.00 %

N/A

N/A
AGES:LSE iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
XHE SPDR® S&P Health Care Eq.. 0.00 % 0.35 %

-1.45 (-0.08%)

USD 0.16B
RTWO:LSE L&G Russell 2000 US Small.. 0.00 % 0.00 %

N/A

USD 0.19B
RTWP:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.19B
WELL:LSE Hanetf Icav - Han-Gins He.. 0.00 % 0.00 %

N/A

N/A
ETLZ:XETRA L&G Russell 2000 US Small.. 0.00 % 0.00 %

+0.37 (+-0.08%)

USD 0.09B
W311:XETRA HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

-0.02 (-0.08%)

N/A
W311:F HAN-GINS Indxx Healthcare.. 0.00 % 0.00 %

+0.02 (+-0.08%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.70% 74% C 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.70% 74% C 89% A-
Trailing 12 Months  
Capital Gain 43.00% 82% B 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 43.00% 82% B 87% B+
Trailing 5 Years  
Capital Gain 760.40% 100% F 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 760.40% 100% F 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 70.19% 84% B 92% A
Dividend Return 70.19% 84% B 91% A-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 65.58% 54% F 28% F
Risk Adjusted Return 107.03% 100% F 98% N/A
Market Capitalization 7.11B 96% N/A 91% A-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.